Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen.
Saved in:
| Title: | Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen. |
|---|---|
| Authors: | Tu, Ya‐Ping1 (AUTHOR) yaping.tu@gmail.com, Lagraauw, H. Maxime2 (AUTHOR), Method, Michael3 (AUTHOR), Wang, Yuemei4 (AUTHOR), Hanze, Eva2 (AUTHOR), Li, Lingling4 (AUTHOR), Parrott, Timothy5 (AUTHOR), Sloss, Callum M.6 (AUTHOR), Westin, Eric H.3 (AUTHOR) |
| Source: | British Journal of Clinical Pharmacology. Jan2025, Vol. 91 Issue 1, p220-231. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 181890234 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Tu%2C+Ya‐Ping%22">Tu, Ya‐Ping</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> yaping.tu@gmail.com</i><br /><searchLink fieldCode="AR" term="%22Lagraauw%2C+H%2E+Maxime%22">Lagraauw, H. Maxime</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Method%2C+Michael%22">Method, Michael</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wang%2C+Yuemei%22">Wang, Yuemei</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hanze%2C+Eva%22">Hanze, Eva</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Li%2C+Lingling%22">Li, Lingling</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Parrott%2C+Timothy%22">Parrott, Timothy</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sloss%2C+Callum+M%2E%22">Sloss, Callum M.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Westin%2C+Eric+H%2E%22">Westin, Eric H.</searchLink><relatesTo>3</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22British+Journal+of+Clinical+Pharmacology%22">British Journal of Clinical Pharmacology</searchLink>. Jan2025, Vol. 91 Issue 1, p220-231. 12p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=181890234 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1111/bcp.16250 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 12 StartPage: 220 Titles: – TitleFull: Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Tu, Ya‐Ping – PersonEntity: Name: NameFull: Lagraauw, H. Maxime – PersonEntity: Name: NameFull: Method, Michael – PersonEntity: Name: NameFull: Wang, Yuemei – PersonEntity: Name: NameFull: Hanze, Eva – PersonEntity: Name: NameFull: Li, Lingling – PersonEntity: Name: NameFull: Parrott, Timothy – PersonEntity: Name: NameFull: Sloss, Callum M. – PersonEntity: Name: NameFull: Westin, Eric H. IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Text: Jan2025 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 03065251 Numbering: – Type: volume Value: 91 – Type: issue Value: 1 Titles: – TitleFull: British Journal of Clinical Pharmacology Type: main |
| ResultId | 1 |
